Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Esophagogastric Cancer 1Breast Cancer Metastases 1

Interventions

Exercise 440Blood Specimen Collection 335Standard of Care 325Magnetic Resonance Spectroscopy 260Radiotherapy 255Surveys and Questionnaires 246Radiosurgery 245Methods 231Educational Status 231Early Intervention, Educational 219Interviews as Topic 149Practice Guidelines as Topic 147Biopsy 146Surgical Procedures, Operative 136Drug Therapy 133Control Groups 128Acupuncture Therapy 124Therapeutics 111Cyclophosphamide 103Palliative Care 101Counseling 101Resistance Training 96Saline Solution 90Cisplatin 90Magnetic Resonance Imaging 89Radiofrequency Ablation 86Specimen Handling 83Radiotherapy, Intensity-Modulated 79Colonoscopy 79Cognitive Behavioral Therapy 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × zirconium-89-trastuzumab × Clear all
NCT02023996 2024-12-10

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
42 enrolled 11 charts
Gastrointestinal

Esophagogastric Cancer

NCT02286843 2021-06-18

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Memorial Sloan Kettering Cancer Center

Phase NA Completed
49 enrolled 8 charts
Breast

Breast Cancer Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡